CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock
CRISPR Therapeutics General Counsel, James Kasinger, sold 2,112 shares of the company's stock for $111,048.96, reducing his stake by 2.42%. This sale followed the company's quarterly earnings report, which showed a significant miss with EPS of ($1.37) against an estimated ($1.15) and revenues down 97.8% year-over-year. Analysts currently have an average target price of $64.24 for CRSP, with a mixed rating of Buy, Hold, and Sell recommendations.
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock
CRISPR Therapeutics CEO Samarth Kulkarni recently sold 6,967 shares for $366,324.86, adding to previous sales in January totaling roughly $5.53 million in CRSP stock, reducing his stake by 2.99%. This comes after the company reported a significant earnings and revenue miss, though institutional ownership is high and analyst ratings average a "Hold" with a $64.24 price target. The company specializes in gene-editing therapies for serious diseases, with its lead program CTX001 for sickle cell disease.
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST)
Morgan Stanley analysts have issued new ratings on several healthcare companies. Terence Flynn maintained a Sell rating on Crispr Therapeutics AG (CRSP) with a $33.00 price target. Judah Frommer gave Galapagos (GLPG) a Sell rating and a $22.00 price target, while Kallum Titchmarsh maintained a Hold rating on West Pharmaceutical Services (WST) with a $285.00 price target.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)
This article summarizes recent analyst ratings for three healthcare companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA), and Disc Medicine (IRON). J.P. Morgan maintained a Buy rating for Crispr Therapeutics, while Bernstein held a Hold rating for Moderna. Stifel Nicolaus reaffirmed a Buy rating for Disc Medicine, reflecting varied analyst sentiments across the sector.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)
Analysts have issued conflicting ratings for several healthcare companies. J.P. Morgan maintained a Buy rating for Crispr Therapeutics AG (CRSP) with an average price target indicating a significant upside. Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA), while Stifel Nicolaus maintained a Buy rating for Disc Medicine (IRON), suggesting a strong upside for the company.
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is currently experiencing unusual volume, leading to increased investor attention. This article aims to provide essential information regarding the company and its recent performance to help investors make informed decisions.
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Short Term Share Price Momentum
CRISPR Therapeutics (CRSP) has seen recent short-term share price momentum but its valuation presents a mixed picture. While its price-to-book ratio of 2.7x is well below the peer group average, it's slightly above the broader US biotech industry, indicating the market values its pipeline. A Discounted Cash Flow model suggests significant undervaluation at current prices, though this depends on the optimism of future cash flow assumptions.
Crispr Therapeutics Stock Target Raised Amidst Positive Momentum
Crispr Therapeutics (CRSP) is experiencing positive momentum due to promising clinical trial results for its Casgevy therapy, leading analysts like Chardan and Evercore ISI to raise their price targets to $76 and $74 respectively, while maintaining "Buy" ratings. Despite current negative profitability margins, the company shows strong liquidity and growth potential, with institutional confidence echoed by ARK Investment's acquisition of CRSP shares. The stock's recent performance reflects robust buying interest, though investors are advised to monitor support and resistance levels.
CRISPR Therapeutics (CRSP) Stock: Why Bad Earnings Sparked a 9% Rally
CRISPR Therapeutics (CRSP) stock unexpectedly rallied 9.2% despite missing Q4 earnings estimates, reporting only $864,000 in revenue. The surge was driven by partner Vertex Pharmaceuticals' optimistic 2026 guidance, projecting over $500 million in non-cystic fibrosis product revenue, largely from increased Casgevy infusions. Casgevy, an FDA-approved gene-editing treatment, saw almost triple the patient initiations in 2025 compared to 2024, with expanding reimbursement coverage in the US, Europe, and the Middle East, signaling strong future revenue potential.
ARK Investment’s Strategic Purchase in CRISPR Therapeutics
ARK Investment has significantly increased its stake in CRISPR Therapeutics, purchasing an additional 247,000 shares, signaling strong confidence despite a disappointing Q4 earnings report. Analyst firms Bank of America and Citizens have adjusted price targets for CRSP, maintaining a "Buy" stance due to the company's promising gene-editing therapies and potential for future growth in its developmental pipeline. This strategic investment by Cathie Wood's ARK is seen as a positive counterbalance to recent financial setbacks, highlighting long-term faith in CRISPR Therapeutics' prospects in the evolving biotech landscape.
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates
CRISPR Therapeutics (CRSP) reported a wider-than-expected loss of $1.37 per share in Q4 2025, missing the Zacks Consensus Estimate, with total revenues also falling short. Despite the financial miss and a stock decline, the company maintains a robust outlook for its Casgevy gene therapy, developed with Vertex Pharmaceuticals, expecting continued sales momentum in 2026. CRSP is also advancing its pipeline with planned label expansions for Casgevy, ongoing development of CAR-T cell therapies, and new in-vivo and RNA therapeutics candidates.
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 8% on Analyst Upgrade
CRISPR Therapeutics (NASDAQ:CRSP) saw its shares jump 8% following an analyst upgrade from Needham & Company LLC, which raised its price target to $82 and maintained a "buy" rating. This occurred despite the company missing its recent quarterly earnings and revenue estimates significantly, with revenue down 97.8% year-over-year. The article also notes a significant insider stock sale by CEO Samarth Kulkarni and details institutional ownership of the company.
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results
CRISPR Therapeutics (NASDAQ:CRSP) reported a Q4 EPS of ($1.37), missing analyst estimates of ($1.16), with deeply negative net margin and return on equity. Despite the earnings miss, shares traded up 1.3%. The company holds a "Hold" consensus rating with an average price target of $66.78, and CEO Samarth Kulkarni recently sold 60,000 shares.
Crispr Therapeutics (CRSP) Reports Lower-Than-Expected Q4 Revenue
Crispr Therapeutics (CRSP) reported a Q4 revenue of $864,000, significantly missing the $4.02 million consensus estimate, despite advancing its gene-editing pipeline across various clinical programs and enhancing platform capabilities. The company, a pioneer in CRISPR/Cas9-based therapeutics with its first approved drug CASGEVY, faces challenges with negative revenue growth and substantial profitability issues, though it maintains strong liquidity and low leverage. Analyst targets reflect a positive outlook, but insider selling and high stock volatility suggest a mixed market sentiment.
CRISPR Therapeutics AG SEC 10-K Report
CRISPR Therapeutics AG has released its 2025 10-K report, highlighting significant financial and operational milestones despite a net loss of $581.6 million. Key achievements include the 2023 approval of CASGEVY, the first CRISPR-based gene-editing therapy, and advancements across its diverse therapeutic program portfolio. The company faces financial, operational, regulatory, and market risks but plans to fund operations through equity, debt, and collaborations, with existing cash expected to last at least 24 months.
CRISPR Therapeutics (CRSP) Q4 Earnings Miss Expectations
CRISPR Therapeutics (CRSP) reported a significant Q4 revenue decline of 97.6% year-over-year, missing analyst expectations, with GAAP EPS also falling short. Despite these financial setbacks and operational inefficiencies leading to negative operating and net margins, the company maintains strong liquidity with increased cash reserves and a low debt-to-equity ratio. Its pioneering work in CRISPR/Cas9-based therapeutics, including the Casgevy product and other gene editing programs, offers potential for future success despite current valuation complexities and market volatility.
Crispr Therapeutics earnings missed by $0.20, revenue fell short of estimates
Crispr Therapeutics (NASDAQ: CRSP) reported fourth-quarter earnings per share (EPS) of $-1.37, missing analyst estimates by $0.20, and revenue of $860K, which fell short of the $5.66M consensus estimate. The company's stock closed at $48.93, showing a 6.85% decrease over the last 3 months but a 12.51% increase over the last 12 months.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
CRISPR Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant advancements across its diverse pipeline. Key achievements include continued global uptake and revenue growth for CASGEVY, positive pediatric data for its pivotal studies, and progress in its in vivo liver editing, siRNA-based, autoimmune, immuno-oncology, and regenerative medicine programs. The company continues to expand its leadership in gene editing and expects further clinical updates and trial initiations in 2026.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates
CRISPR Therapeutics AG (CRSP) reported a Q4 loss of $1.37 per share, significantly missing the Zacks Consensus Estimate of a $1.15 loss. The company's revenues of $0.86 million also fell short of estimates by 78.42%. Despite past performance, the stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
CRISPR Therapeutics announced its financial results for Q4 and full year 2025, highlighting continued progress across its pipeline. The company reported $54 million in Q4 and $116 million in full-year 2025 revenue for CASGEVY, with patient initiations and cell collections increasing significantly. Additionally, CRISPR Therapeutics provided updates on its in vivo liver editing programs, siRNA-based therapies, autoimmune disease and immuno-oncology initiatives, and regenerative medicine portfolio, with several clinical trial initiations and data updates expected in 2026.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) is gaining investor attention due to recent stock performance and upcoming earnings. Over the past month, CRSP shares returned -18.7%, underperforming the Zacks S&P 500 composite. Analysts predict a loss of $1.15 per share for the current quarter and anticipate significant revenue growth in the next fiscal year, driving the company's Zacks Rank to #3 (Hold).
CRISPR Therapeutics AG $CRSP Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd
IQ EQ FUND MANAGEMENT IRELAND Ltd significantly increased its stake in CRISPR Therapeutics AG (CRSP) by 44.7% in Q3, now owning 283,111 shares worth $18.35 million. This makes CRSP its 16th largest position, accounting for 1.2% of its portfolio. Various other hedge funds also adjusted their holdings, while CEO Samarth Kulkarni sold 60,000 shares, reducing his ownership to 4.3% of the company.
Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline
Citizens maintained an Outperform rating on CRISPR Therapeutics (CRSP) despite reducing its price target from $86 to $80, citing that much of the company's pipeline remains undervalued and anticipates late-stage development for up to seven opportunities in 2027. This follows a similar sentiment from Bank of America, which also reduced its price target but maintained a Buy rating, highlighting aligning factors for biotech growth. CRISPR Therapeutics is a gene editing company, though the article suggests that certain AI stocks may offer greater promise and lower risk for investors.
Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline
Citizens maintained an "Outperform" rating on CRISPR Therapeutics (CRSP) despite reducing its price target, citing an undervalued pipeline with potential for late-stage development in multiple opportunities by 2027. This follows a similar sentiment from Bank of America, which also maintained a "Buy" rating. The article suggests that while CRSP has potential, certain AI stocks might offer greater upside and less risk.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
CRISPR Therapeutics AG (CRSP) is anticipated to surpass its earnings estimates for the quarter ending December 2025, despite an expected year-over-year decline in earnings and revenue. The company has a positive Earnings ESP of +15.85% and a Zacks Rank of #3, indicating a high probability of an earnings beat. Historically, CRISPR Therapeutics has beaten EPS estimates in three of the last four quarters.
CRISPR Therapeutics (CRSP) Price Target Increased by 14.61% to 82.91
The average one-year price target for CRISPR Therapeutics (CRSP) has increased by 14.61% to $82.91 per share, up from $72.34. This new target represents a 61.59% increase from the last reported closing price of $51.31 per share. Institutional ownership data indicates a bullish outlook, with several major firms adjusting their holdings in CRSP.
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
CRISPR Therapeutics (CRSP) is expected to outperform expectations in its upcoming fourth-quarter and full-year 2025 earnings report, with an Earnings ESP of +15.85% and a Zacks Rank #3. The company's top line is largely driven by collaboration revenues from its partnership with Vertex Pharmaceuticals for the gene therapy Casgevy, which was approved for two blood disorders. Investors will also be keen on updates regarding Casgevy's label expansion, new CAR-T cell therapies, and in-vivo candidates in its pipeline.
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Tuesday
CRISPR Therapeutics (CRSP) is scheduled to release its Q4 2025 earnings before market open on Tuesday, February 10th, with analysts expecting a loss of ($1.16) per share. For the previous quarter, the company reported an EPS of ($1.17), surpassing the consensus estimate. The article also details recent insider stock sales, institutional investor activity, and current analyst ratings for CRSP.
Does CRISPR Therapeutics (CRSP) Pipeline Expansion And ARK’s Buying Redefine Its Long‑Term Narrative?
CRISPR Therapeutics (CRSP) has outlined its 2026 milestones, including the continued rollout of Casgevy and advancements in other gene-editing programs, while ARK Investment Management has been increasing its stake in the company. This suggests institutional confidence in CRISPR's high-risk, high-reward platform, moving beyond rare blood disorders into broader applications. However, significant challenges remain, such as Casgevy's early rollout phase and the early-to-mid-stage nature of the rest of the pipeline, coupled with persistent cash burn and varying fair value estimates among analysts.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
CRISPR Therapeutics AG (CRSP) shares recently rose by 2.7%, outperforming the S&P 500. While the stock has seen a monthly decline, largely lagging its sector, investors are anticipating upcoming earnings, with projections indicating a significant drop in EPS and revenue year-over-year. The company currently holds a Zacks Rank #3 (Hold), influenced by a recent slight downward revision in its consensus EPS projection.
Does CRISPR Therapeutics (CRSP) Pipeline Expansion And ARK’s Buying Redefine Its Long‑Term Narrative?
CRISPR Therapeutics (CRSP) has outlined its 2026 milestones, focusing on expanding Casgevy's rollout, advancing gene-editing programs, and planned regulatory filings. ARK Investment Management has increased its stake in CRSP, highlighting institutional confidence in the company's high-risk, high-upside CRISPR/Cas9 platform. While these developments strengthen the long-term narrative, the company still faces challenges with Casgevy's early rollout and early-to-mid-stage pipeline, making it sensitive to execution and potential regulatory setbacks.
ARK’s Bigger CRISPR Therapeutics Stake Underscores Gene Editing Pipeline Story
ARK Investment Management has significantly increased its stake in CRISPR Therapeutics (CRSP), signaling confidence in the company's gene editing technology and diverse clinical pipeline. This investment highlights CRISPR's potential in treating various conditions, including beta-thalassemia, sickle cell disease, cardiovascular issues, and type 1 diabetes. Despite a mixed stock performance history, ARK's move emphasizes the importance of current execution and progression in CRISPR's multi-faceted gene editing platform.
ARK’s Bigger CRISPR Therapeutics Stake Underscores Gene Editing Pipeline Story
ARK Investment Management has significantly increased its stake in CRISPR Therapeutics, signaling strong confidence in the company's gene editing pipeline across various high-need medical areas like sickle cell disease, beta thalassemia, cardiovascular conditions, and type 1 diabetes. This move highlights CRISPR Therapeutics' potential as a platform company with multiple therapeutic programs beyond its single product, Casgevy, despite its current unprofitability and inherent risks in the complex gene editing field. Investors are advised to monitor ARK's future trading, regulatory milestones for Casgevy, and data from new programs like CTX310 and CTX211.
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally
CRISPR Therapeutics (CRSP) saw a significant stock jump of 9.6% during a broader biotech sector rally. This positive movement aligns with the company's strong performance, having gained 29.5% year-to-date, outperforming both its industry and the S&P 500. Investors are anticipating a potential breakout, driven by recent strategic expansions and strong financial positions.
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at Citizens Jmp
Citizens Jmp has lowered its price target for CRISPR Therapeutics (NASDAQ:CRSP) to $80.00 from $86.00, while maintaining a "market outperform" rating, implying a potential 52% upside. This outlook contrasts with the more cautious average analyst consensus of a "Hold" rating and a $67.85 target. The company currently faces profitability challenges, reporting a negative EPS and net margin, and its CEO recently sold a significant portion of his shares.
What Does the Market Think About CRISPR Therapeutics AG?
CRISPR Therapeutics AG (CRSP) has seen a 3.73% decrease in its short interest, with 21.05 million shares sold short, representing 24.8% of its float. While the decline suggests a potentially more bullish sentiment, CRSP's short interest remains higher than its peer group average of 15.14%. It would take traders an average of 14.19 days to cover their short positions.
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch
CRISPR Therapeutics is a biotech company specializing in gene-editing therapies for difficult-to-treat diseases that Artificial Intelligence cannot address. The company has several promising candidates, including treatments for Type 1 diabetes, anticoagulation, and high cholesterol, and has already secured approval for Casgevy for rare blood disorders. While CRISPR Therapeutics offers potential for strong returns, investors should be aware of the inherent risks associated with clinical and regulatory setbacks and the high cost of gene-editing medicines.
BofA is Bullish on CRISPR Therapeutics AG (CRSP)
BofA maintained a buy rating on CRISPR Therapeutics AG (CRSP) despite slightly lowering its price objective from $90 to $89 due to revised Casgevy 2026 projections. The firm still anticipates consecutive improvement for Casgevy throughout 2026 and expects regulatory submissions for younger patients and advancements in other clinical programs. CRISPR Therapeutics announced strategic priorities for 2026, including Casgevy's global commercialization and clinical trial initiations for new therapies.
BofA is Bullish on CRISPR Therapeutics AG (CRSP)
BofA maintains a bullish outlook on CRISPR Therapeutics AG (CRSP) despite a slight reduction in its price objective from $90 to $89 due to revised 2026 Casgevy projections. The company announced its 2026 milestones, including anticipated Casgevy regulatory submissions for younger patients, advancements in various clinical programs, and upcoming clinical trials for CTX460 and CTX340. BofA still expects continuous improvement for Casgevy through 2026.
Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy
The Chief Marketing Officer of Crispr Therapeutics AG, Naimish Patel, recently purchased 1,508 shares of the company's stock for $49,703, indicating confidence in the firm's future. TipRanks' AI Analyst, Spark, rates CRSP as "Neutral" due to weak financial performance despite a solid balance sheet. The stock's year-to-date performance is 4.21%, with a current market cap of $5.21 billion.
CRISPR Therapeutics (NASDAQ:CRSP) Insider Purchases $49,703.68 in Stock
CRISPR Therapeutics insider Naimish Patel recently acquired 1,508 shares of the company's stock, totaling $49,703.68. The transaction increases Patel's ownership to 1,508 shares. The company, which has a market cap of $5.17 billion, reported quarterly EPS of ($1.17) and revenue of $0.89 million, and it holds a consensus "Hold" rating from analysts with an average target price of $68.15.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRISPR Therapeutics AG (CRSP) stock dropped 1.57% while the broader market gained, closing at $54.65. Analysts anticipate a significant year-over-year decline in upcoming earnings and revenue. The stock currently holds a Zacks Rank of #3 (Hold), with the industry ranking in the top 36%.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRISPR Therapeutics AG (CRSP) stock fell by 1.57%, underperforming the broader market which saw gains in the S&P 500, Dow, and Nasdaq. Analysts anticipate a significant year-over-year decline in earnings and revenue for CRSP's upcoming financial report. The company currently holds a Zacks Rank of #3 (Hold), with its industry ranked in the top 36%.
CRISPR Therapeutics stock drops 9% after CEO sale filing — what CRSP investors watch next week
CRISPR Therapeutics (CRSP) stock dropped 8.7% after its CEO, Samarth Kulkarni, filed to sell 90,000 shares under a prearranged 10b5-1 plan. Despite the sale being pre-scheduled, the news contributed to a broader biotech sector pullback. Investors are now focused on Monday's trading to see if the sell-off continues and on the company's upcoming quarterly report on February 17th, with concerns over the slow rollout of Casgevy potentially impacting future performance.
Did CEO Share Sale and Casgevy Rollout Just Shift CRISPR Therapeutics' (CRSP) Investment Narrative?
CRISPR Therapeutics is under investor scrutiny due to a pre-arranged share sale by CEO Samarth Kulkarni and the early commercial rollout of its gene-edited therapy, Casgevy. While analysts maintain constructive views, near-term earnings estimates have been trimmed, highlighting execution risks and potential dilution. The company's future hinges on Casgevy's commercial uptake and progress in other pipeline programs.
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 5.8% on Insider Selling
CRISPR Therapeutics (NASDAQ:CRSP) shares dropped 5.8% after CEO Samarth Kulkarni sold a total of 90,000 shares in two separate transactions, reducing his stake significantly. The stock traded with lower-than-average volume, closing at $57.2870. The company has a mixed analyst consensus of "Hold" with an average price target of $68.15.
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $89.00 by Analysts at Bank of America
Bank of America has reduced its price target for CRISPR Therapeutics (NASDAQ:CRSP) from $90.00 to $89.00, while maintaining a "buy" rating, indicating a potential upside of 46.7% from its current price. Despite this, other analysts have mixed ratings, with an average price target of $68.15. Additionally, CRISPR Therapeutics' CEO, Samarth Kulkarni, sold 60,000 shares, decreasing his ownership by 30.9%.
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing
CRISPR Therapeutics (NASDAQ: CRSP) shares slipped in premarket trading after an 11.1% surge the previous day, influenced by an SEC filing revealing CEO Samarth Kulkarni sold 90,000 shares totaling $5.2 million under a pre-arranged plan. Despite the insider sale and a trimmed price target from Bank of America, options trading activity increased, keeping the gene-editing stock in focus. The company's Casgevy therapy, developed with Vertex Pharmaceuticals, surpassed $100 million in revenue in 2025, but its commercial rollout, dependent on complex hospital protocols and reimbursement, remains a key variable for investors.
CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 30,000 Shares of Stock
CRISPR Therapeutics CEO Samarth Kulkarni sold 30,000 shares of the company's stock on January 20th at an average price of $51.75, totaling over $1.55 million. This transaction reduced his direct holdings to 194,201 shares, a 13.38% decrease. An additional sale of 60,000 shares occurred on January 22nd for over $3.6 million.
Samarth Kulkarni Sells 60,000 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock
Samarth Kulkarni, CEO of CRISPR Therapeutics (NASDAQ:CRSP), sold 60,000 shares of the company's stock for over $3.6 million, reducing his position by 30.9%. This transaction occurred on January 22nd, with shares trading up 10.8% on high volume. Analyst sentiment for CRSP is mixed, with a consensus "Hold" rating and an average price target of $68.35, despite the company beating EPS estimates but missing revenue significantly in its last quarterly report.
